Trials / Completed
CompletedNCT00082524
Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 3 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open label, noncomparative study using an investigational agent for the treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3 months-17 years).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | caspofungin acetate | Duration of Treatment - 7-90 days |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2007-07-01
- Completion
- 2007-07-01
- First posted
- 2004-05-13
- Last updated
- 2017-02-23
Source: ClinicalTrials.gov record NCT00082524. Inclusion in this directory is not an endorsement.